Biogen's Qalsody approved in European Union to treat SOD1-ALS
The European Commission has approved Qalsody to treat ALS patients in the EU whose disease is associated with mutations in the SOD1 gene.| ALS News Today
About 90% of cases of amyotrophic lateral sclerosis (ALS) are characterized as sporadic ALS, meaning they occur spontaneously.| ALS News Today
The European Commission has approved Qalsody to treat ALS patients in the EU whose disease is associated with mutations in the SOD1 gene.| ALS News Today
The FDA granted conditional approval to tofersen, now Qalsody, for the treatment of ALS associated with mutations in the SOD1 gene.| ALS News Today
Qalsody (tofersen) is conditionally approved in the U.S. as treatment for amyotrophic lateral sclerosis associated with SOD1 gene mutations.| ALS News Today
When more than one person in the same biological family is affected by amyotrophic lateral sclerosis (ALS), it is known as familial ALS.| ALS News Today
Marisa Wexler is a senior science writer for ALS News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of amyotrophic lateral sclerosis topics.| ALS News Today
ALS is a neurodegenerative condition that affects motor neurons. Learn about the causes and risk factors of ALS.| ALS News Today
Category archive page for News.| ALS News Today
Clene submitted new data on CNM-Au8 to the FDA ahead of an upcoming meeting to discuss potential accelerated approval for the ALS therapy.| ALS News Today
ALS is a progressive neurological disorder that damages motor neurons. Learn more about types, causes, symptoms, diagnosis, and treatment.| ALS News Today
